Biohaven Pharmaceuticals are working with Engage Health on this research project to learn more from families impacted by SCA types 1, 2, 3, or 6 regarding the burden and impact …
Research project – understanding the spectrum of SCA1, SCA2, SCA3 & SCA6 Read More »
Biogen announce new clinical trial for SCA3 Biogen have announced that they are starting a Phase I clinical trial for their Spinocerebellar Ataxia Type 3 (SCA3) treatment BIIB132. A Phase …
The research that Ataxia UK funds has a real impact on the world of ataxia research, and our understanding of all ataxias. Every year we ask Ataxia UK-funded researchers to …
Novartis Gene Therapies have announced an update on a gene therapy that they have been developing for Friedreich’s Ataxia (FA) called OAV401. Novartis Gene Therapies develops and commercialises gene therapies for rare genetic conditions, such as FA. They have …
Update from Novartis Gene Therapies on treatment for FA Read More »
Read a summary of the impact of Ataxia UK-funded research in the Research Impact Report 2020
Triplet Therapeutics are developing a new treatment that aims to address the underlying cause of the genetic dysfunction responsible for repeat expansion disorders including various SCAs.
We are gathering information from people with ataxia to help the Scottish Medicines Consortium make an informed decision about a medicine used to treat excessive drooling as a symptom of a neurological condition.
Ataxia UK uses Researchfish to analyse the impact of Ataxia UK-funded research. This report summarises data from 39 grants, awarded between 2009 and 2018.
Ataxia UK welcomes the news that Leiden-based biotech company ProQR are expanding their research interests and are now working on Friedreich’s ataxia. Dr Julie Greenfield, Ataxia UK’s Research Manager says …
